Results for tag: "Uremic Pruritus Drug"

Uremic pruritus, also known as chronic kidney disease-associated pruritus (CKD-aP), is a common symptom in patients with advanced or end-stage renal disease. It is characterized by intense itching and is associated with a considerable decrease in the quality of life. Within the dermatological drugs market, treatments for uremic pruritus are a specialized niche focused on alleviating this distressing symptom. The therapeutic strategies include various topical and systemic medications. Topical treatments such as emollients, capsaicin cream, and calcineurin inhibitors aim to soothe the skin and reduce itching. Systemic treatments typically involve antihistamines, gabapentinoids, and opioid receptor antagonists, which target the central and peripheral pathways involved in pruritus. Another aspect of the market is dedicated to addressing the underlying kidney disease and includes phosphate binders and dialysis optimization. In recent years, there has been an increasing focus on the development of novel therapies specifically designed to target the pathophysiology of uremic pruritus. This has led to the emergence of new treatments that promise improved efficacy and safety profiles. Some notable companies that are either directly involved in the uremic pruritus drug market or have products that address symptoms associated with it include Sanofi, Pfizer, Novartis, and Galderma. Other companies that have been developing specialized treatments for CKD-associated pruritus include Vifor Pharma, Cara Therapeutics, and Trevi Therapeutics Show Less Read more